Mr Paul Hopper - Non-Executive Chairman
Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies with extensive capital markets experience in equity and debt raisings in Australia, Asia, US and Europe.
Mr Hopper's sector experience has covered a number of therapeutic areas including anti-bacterials, medical devices, antibodies, inflammation and oncology, with a particular emphasis on cancer vaccines. Mr Hopper is also a Director of Boston based pSivida Corp a drug delivery company which has completed Phase III trials for ophthalmology, Somnomed Limited (ASX:SOM) which globally manufactures and markets a dental device for sleep disorders and iSonea which manufactures and markets respiratory devices with a focus on asthma. Paul is Head of the Australia Desk and Head of the Life Sciences and Biotechnology practice at the Los Angeles merchant bank Cappello Capital where he is a partner. He also serves as a Director of the American Australian Association and is a member of the Queensland North America Biotechnology Advisory Council.
Mr Hopper has served on the boards of many listed biotechnology and healthcare companies including as Executive Chairman of Bone Medical Limited, Director of Advanced Biotherapy Inc, Managing Director of Australian Cancer Technology Limited, and Director of Medaire Ltd. He was the co-founder and Managing Director of Alpha Healthcare Limited. He is based in Los Angeles.
Mr Bryan Dulhunty BEc CA – Managing Director
Mr Dulhunty‟s background is primarily financial and management of long term capital intensive development projects. Initial experience was gained with one of the big four audit firms before moving to one of the world's largest international companies. Mr Dulhunty became involved in the biotechnology industry in the mid 1990's and shortly thereafter established his own financial management and financial assurance company focusing on biotechnology companies, both listed and unlisted. Mr Dulhunty has been on the board of a number of listed and unlisted biotechnology companies but has focused his activities on Viralytics since 2006.
Dr Leonard Post - Non-Executive Director
Dr Post has extensive experience in oncolytic viruses and virotherapy having been a past director of and consultant to Biovex Ltd, recently acquired by Amgen Inc. He was also Senior Vice President of R&D at Onyx Pharmaceuticals which was one of the first companies involved in the development of targeted oncolytic viruses. Prior to this, Dr Post’s experience covers almost 20 years with large international pharmaceutical companies.
Dr Post has a strong commercial background which includes founding US-based LEAD Therapeutics Inc. in 2007 which was subsequently acquired by BioMarin Pharmaceuticals Inc in 2010. Dr Post currently holds the position of Chief Scientific Officer of BioMarin Pharmaceuticals Inc. Dr Post is also an advisor to an well known Australian based venture capital firm.
Dr Post is a director of two USA-based biotechnology companies and has been a member of a number of Scientific Advisory Boards.
Dr Phillip Altman B.Sc (Hons) M.Sc Ph.D – Non-Executive Director
Dr Altman is a well known Australian authority on clinical trials and regulatory affairs with more than 30 years experience in clinical research and regulatory affairs. He is a graduate of Sydney University with an honours degree in Pharmacy, Master of Science and Doctor of Philosophy (pharmacology and pharmaceutical chemistry) degrees. Dr Altman also co-founded and is a Life Member of the largest professional body of pharmaceutical industry scientists involved in clinical research and regulatory affairs (Association of Regulatory and Clinical Scientists to the Australian Pharmaceutical Industry Ltd – ARCS). In addition to working in senior management positions for several multinational companies, including Merrell-Dow, Hoechst, Roussel and GD Searle, Dr Altman established his own company, Pharmaco Pty Ltd, one of the first contract research organizations where he served as a Senior Industry Consultant and he continues to provide consultant support for a range of companies.
Mr Peter Molloy - Non-Executive Director
Mr Molloy is a successful Australian pharmaceutical and biotechnology executive and now an industry consultant and director. In addition to Viralytics, he is a director of Parnell Pharmaceuticals and Synthesis Med Chem USA Inc. Previously, Mr Molloy was the Managing Director and CEO of ASX-listed Biota Holdings Limited (2002-2005), Australia‟s premier antiviral drug development company. His previous executive roles in the biotechnology sector included President and CEO of SLIL Biomedical Corp, a Madison Wisconsin based cancer and viral research company; managing director and CEO of Florigene Limited, a Melbourne based biotechnology company focused on genetic modification of plants; and President of Moleculon Inc, a Boston based transdermal drug delivery company.
Mr Molloy has lived and worked in the US for more than 13 years. In addition to this valuable US perspective, he brings considerable big pharmaceutical company experience. He worked as a pharmaceutical marketing executive for 17 years (1979-1996) with his last role as Vice President of Strategic Marketing for Pharmacia. Pharmacia at the time was one of the top 20 global pharmaceutical companies (now part of Pfizer). Over the years Mr Molloy has been involved in the licensing, clinical development and launch of many new pharmaceutical products in Australia. At Pharmacia he was responsible for evaluating new drug candidates and coordinating the launch and marketing strategy for more than 50 pharmaceuticals across 23 countries.
Mr Molloy is a fellow of the Australian Institute of Company Directors and has served on several Australian and US boards, both as managing director and non executive director, including as chairman of two international businesses. He has been a consultant to several Australian and US companies and a guest speaker on licensing and business development at industry meetings including BIO, the Australian Biotech Summit and the Ausbiotech National Conference. He holds a BSc in Microbiology and Biochemistry from the University of Melbourne and an MBA from the University of Adelaide.